Welcome to CDC Stacks | Digitoxin and its analogs as novel cancer therapeutics - 11052 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Digitoxin and its analogs as novel cancer therapeutics
  • Published Date:
    Apr 05 2012
  • Source:
    Exp Hematol Oncol. 2012; 1:4.
Filetype[PDF - 1.35 MB]


Details:
  • Description:
    A growing body of evidence indicates that digitoxin cardiac glycoside is a promising anticancer agent when used at therapeutic concentrations. Digitoxin has a prolonged half-life and a well-established clinical profile. New scientific avenues have shown that manipulating the chemical structure of the saccharide moiety of digitoxin leads to synthetic analogs with increased cytotoxic activity. However, the anticancer mechanism of digitoxin or synthetic analogs is still subject to study while concerns about digitoxin's cardiotoxicity preclude its clinical application in cancer therapeutics. This review focuses on digitoxin and its analogs, and their cytotoxicity against cancer cells. Moreover, a new perspective on the pharmacological aspects of digitoxin and its analogs is provided to emphasize new research directions for developing potent chemotherapeutic drugs.

  • Document Type:
  • Collection(s):
No Related Documents.
You May Also Like: